Nektar Therapeutics launches Inheris Biopharma

Inheris will be responsible for launch preparation and commercialization for NKTR-181, a novel, first-in-class, investigational opioid molecule. NKTR-181 is currently under review with the U.S. Food and Drug The post Nektar Therapeutics launches Inheris Biopharma appeared first on Pharmaceutical Business review.

UCSF doses first patient in triple combination clinical trial of OncoSec’s TAVO, Epacadostat and KEYTRUDA

The study is being led by Dr. Chase Heaton, M.D., a leading oncologic head and neck surgeon at UCSF, and was developed in collaboration with Dr. Alain Algazi, The post UCSF doses first patient in triple combination clinical trial of OncoSec’s TAVO, Epacadostat and KEYTRUDA appeared first on Pharmaceutical Business review.

Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials

QVM149 is a combination of indacaterol acetate, glycopyrronium bromide and mometasone furoate, which was delivered with the dose-confirming BreezhalerIGB gas pipeline inhalation device during the mid-stage trials. The The post Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials appeared first on Pharmaceutical Business review.

GSK gets Chinese approval for shingles vaccine Shingrix

Shingrix is a non-live and recombinant subunit adjuvanted vaccine, which will be administered intramuscularly in two doses. Shingles is caused by the reactivation of the varicella zoster virus The post GSK gets Chinese approval for shingles vaccine Shingrix appeared first on Pharmaceutical Business review.

Cyclica launches new multi-targeted drug design technology Ligand Design

This revolutionary platform empowers scientists in the pharmaceutical industry to generate novel drug-like compounds by combining powerful methods for molecule generation, ADMET prediction, and high-throughput ligand-protein interaction prediction. The post Cyclica launches new multi-targeted drug design technology Ligand Design appeared first on Pharmaceutical Business review.

FDA approves SORILUX for adolescent plaque psoriasis

SORILUX is now approved for treating plaque psoriasis of the scalp and body in patients aged 12 years and older. The FDA approved SORILUX in 2010 based on The post FDA approves SORILUX for adolescent plaque psoriasis appeared first on Pharmaceutical Business review.

Amgen to acquire Danish firm Nuevolution for £132m

Based in Copenhagen, Nuevolution shares its advanced discovery platform and programmes with pharmaceutical and biotechnology companies to develop novel medical treatment options for the patients. Amgen’s offer represents The post Amgen to acquire Danish firm Nuevolution for £132m appeared first on Pharmaceutical Business review.

Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease

Patients treated with mirikizumab in the SERENITY Phase 2 study achieved significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. The The post Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease appeared first on Pharmaceutical Business review.

WuXi Biologics signed letter of intent for long-term vaccine manufacturing contract

WuXi Vaccines is a joint venture company to be established between WuXi Biologics and Shanghai based Hile Bio-Technology (stock code 603718.SH). The business model of WuXi Vaccines is The post WuXi Biologics signed letter of intent for long-term vaccine manufacturing contract appeared first on Pharmaceutical Business review.

Merck to buy Peloton Therapeutics in £1.72bn deal

Under the deal, Merck’s subsidiary will purchase all outstanding shares of Peloton in exchange for an upfront payment of $1.05bn (£825m) in cash. The shareholders of Peloton will The post Merck to buy Peloton Therapeutics in £1.72bn deal appeared first on Pharmaceutical Business review.